Background: Concomitant administration of radiation therapy (RT) and chemotherapy with cisplatin (CCRT) is considered standard treatment in patients with locally advanced nasopharyngeal cancer (LA-NPC). The role of induction chemotherapy (IC) when followed by CCRT in improving locoregional control remains controversial. Results: Sixty-two patients (86%) received three cycles of IC. No difference between the arms was observed in the number of patients who completed RT (61 versus 64, P = 018). Overall and complete response rates were very similar in the two arms and so were 3-year progression-free and overall survival rates. Grade III or IV toxic effects from IC were infrequent, apart of alopecia. Mucositis, weight loss and leukopenia were the most prominent side-effects from CCRT.
introduction Nasopharyngeal cancer (NPC) is a tumor of epidermoid origin. Its incidence varies among different ethnic groups with the highest incidence reported in Southeast Asia, North Africa, Alaska and the Mediterranean basin [1] . The undifferentiated type, strictly associated with Epstein-Barr virus (EBV) infection, is predominant in Asian and African areas, while the differentiated and the nonkeratinizing squamous cell variants are accounting for 50%-75% of NPCs in the United States [2] .
Radiation therapy (RT) appears to be the treatment of choice for the early NPC [3] , providing complete local control in 80%-90% of cases. However, the majority of patients with NPC present with locally advanced disease, where RT alone represents a poor therapeutic option [4] . Due to the apparent chemosensitivity of the disease, the role of chemotherapy, mainly platinum-based, was evaluated either before RT, as induction chemotherapy (IC), or concomitantly with RT (CCRT).
IC followed by RT appears to prolong progression-free survival (PFS), however a clear benefit in overall survival (OS) had not been demonstrated [5, 6] . CCRT, with cisplatin given at a dose of 100 mg/m 2 every 3 weeks, was clearly demonstrated to have an OS advantage compared with RT alone [7] and was established as the new standard treatment in locally advanced NPC (LA-NPC). However, despite the validation of this finding in a number of randomized studies (reviewed in ref. [8] ), the optimal chemotherapeutic regimen combined with RT has not been determined, with cisplatin also being effective when administered weekly at a dose of 40 mg/m 2 in some studies [8, 9] . Nevertheless, CCRT may not be adequate for certain high-risk patient groups, especially patients with bulky and/or extensive nodal disease who have higher potential for metastasis [10] . Adding IC might be a reasonable approach in such patients [10] . Epirubicin and cisplatin are two of the most active drugs in the management of NPC [11] , while paclitaxel has also shown considerable activity [12, 13] . We have previously reported our experience using IC with a combination of the three most active drugs, i.e. cisplatin, epirubicin and paclitaxel (CEP) followed by CCRT with cisplatin. CEP was well tolerated and resulted in a promising 15% complete response (CR) rate [14] , which is in the range reported with other triplet IC regimens [15] .
Building upon this information, we designed the present study to compare IC with three cycles of CEP followed by CCRT with CCRT alone. The primary objective of the study was overall response rate (ORR). Secondary objectives were acute toxicity, PFS, rate of distant metastases and OS. Furthermore, we explored the predictive/prognostic role of the expression of a number of key regulatory proteins involved in cell proliferation and immortalization. Due to space limitations that apply to the printed version of the journal, complete methods, results and discussion of the biomarker studies are presented in the longer version of this paper (available in Annals of Oncology online).
patients and methods
In order to be eligible for this study, all patients had to have: (i) biopsy-proven, previously untreated WHO type I, II or III NPC; (ii) age ‡15 years; (iii) stage IIB-IVB according to the American Joint Committee on Staging of Cancer classification (AJCC 2002); (iv) measurable or evaluable disease; (v) no other primary tumors; (vi) performance status (PS) of 0-2 according to the Eastern Cooperative Oncology Group scale (ECOG); (vii) adequate bone marrow, hepatic, renal and pulmonary function; (viii) adequate nutritional status to tolerate protocol treatment and (ix) adequate mental status to follow instructions, keep appointments and provide written informed consent.
The clinical protocol was approved by the Hellenic Cooperative Oncology Group (HeCOG) Protocol Review Committee and the institutional review boards in participating institutions. The study was registered at the Australian New Zealand registry (ACTRN 12609000730202). Before randomization, each patient provided a studyspecific written informed consent. [14, 16] . All patients received external beam RT by conventional fractionation; 66-70 Gy (in 6.5-7 weeks) were delivered to the primary tumor, 66 Gy to clinically involved nodes <3 cm, 70 Gy to nodes ‡3 cm and 50 Gy to uninvolved cervical and supraclavicular areas. Treatment was carried out using a 6-megavolt linear accelerator or, in 16 patients, with photon beams of a cobalt-60 unit. For tumor localization, all patients were simulated and simulator films were taken. Following this, computed tomography (CT) scans with slices measuring 5 mm were obtained from 2 cm above the superior orbital ridge (to include the skull base) to the arch of the aorta inferiorly. They were used to assess the extent of the primary tumor, as well as the neck nodes. Three-dimensional conformal treatment planning followed for all patients, except 62 patients who were treated in a single center, where only two-dimensional radiotherapy was available at that time. For details on RT fields and target doses please see longer version of this paper (available as supplementary data in Annals of Oncology online).
Hematologic toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTC, version 3.0). Nonhematologic toxic effects from IC were assessed according to the NCI-CTC and those from CCRT according to the Radiation Therapy Oncology Group (RTOG) criteria.
Response was assessed centrally according to the World Health Organization criteria (for details see the longer version of this paper, available as supplementary data in Annals of Oncology online). A Quality Control Review (QCR) of the RT medical records in a cohort of 110 patients (78%) was carried out by two independent, experienced in Head and Neck Oncology, radiation oncologists blinded as to the patients' clinical outcome, according to the criteria adopted by RTOG [17] . The QCR consisted of a comprehensive reevaluation of the treatment that was actually delivered, rather than intended. For each of the enrolled patients, judgments were made about compliance with the treatment field borders, total dose, fractionation and total elapsed days relative to the protocol prescription at the primary site, regional nodes and any critical structures. Each parameter was categorized as: (i) per protocol, (ii) minor deviation, (iii) major deviation acceptable, (iv) major deviation unacceptable, (v) nonevaluable [17] . The criteria for each parameter were defined before the QRC was carried out.
statistical analysis
The present study was done on an 'intent-to-treat' basis and thus, all eligible patients were included in the analysis. The sample size was calculated on the assumption that a 20% difference in ORR, from a baseline of 70%, existed between the two groups. For a two-sided test with a and b errors of 0.05 and 0.20, respectively, 72 patients were required per group. An interim analysis based on the O'Brien-Fleming boundary values was planned, when 74 patients had been evaluated for response. The study did not stop prematurely at the interim analysis.
Differences between groups were evaluated using Fisher's exact and chisquare tests for categorical variables and the Mann-Whitney U test for continuous variables (two-sided tests). OS was measured from the date of randomization to patient's death or last contact. PFS was measured from the original articles Annals of Oncology date of randomization to documented disease progression, death without prior documented progression or last contact. OS and PFS were estimated by the Kaplan-Meier method and differences between survival curves were assessed using the log-rank test.
Predictive and prognostic factor analyses were carried out with logistic regression for ORR and the Cox proportional hazards model for PFS and OS. For model selection, a backward procedure was used with a removal criterion of P > 0.10 that identified the subclasses of significant variables among examined biomarkers, basic clinicopathologic characteristics and treatment group. For all comparisons, the level of significance was set at a = 0.05. (M1) disease at study entry and were considered noneligible. Among the 141 eligible patients, 72 in the investigational and 69 in the control arm, 5 (4 versus 1) never started treatment. Two of these patients, one in each arm, both over 80-year-old women with bulky disease (T 4 N 3b M0), died suddenly a few days before the initiation of treatment, probably due to the disease. Three patients withdrew consent. The progress of patients through the various stages of the trial is shown in Figure 1 , according to the recent version of the Consolidated Standards of Reporting Trials [18] .
Selected patient and tumor characteristics are presented in Table 1 . In the investigational arm, 66 patients (92%) received at least one cycle of IC. Five protocol violators received only CCRT, one received paclitaxel instead of cisplatin during CCRT and four never started treatment, as previously stated. Totally, 62 patients (86%) in the investigational arm received three cycles of IC, as planned. Reasons for treatment Annals of Oncology original articles discontinuation were early death due to rapid tumor progression 1 week before cycle 3, grade III peripheral neuropathy, acute myocardial infarction after cycle 2 and progressive disease after cycle 2 (each in one patient). Median time interval between cycle 1 and 2 and between cycle 2 and 3 was 21 days (17-29 days) and 21 days (19- During CCRT, the percentage of patients receiving 8, 7, 6, 5, 4, 3 and 2 infusions of weekly cisplatin was 8%, 32%, 20%, 12%, 20%, 3% and 5%, respectively in the investigational arm and 9%, 39%, 23%, 17%, 9%, 1% and 3%, respectively in the control arm (P = 0.52). Furthermore, among patients who actually received CCRT, 38 out of 66 in the investigational arm (57.6%) and 51 out of 68 patients in the control arm (75%) received a cumulative dose of ‡200 mg/m 2 (P = 0.044). Finally, no difference was observed in the number of patients who completed RT (61 in the investigational and 64 in the control arm, P = 0.18). Three-dimensional conformal RT by conventional fractionation was administered to all except 62 patients who were treated in a single center with two-dimensional RT, since it was the only treatment available at the specific center. These patients were balanced between the two arms of the study (31 versus 31) and thus, RT was not found to be a significant variable in the multivariate logistic or Cox models for ORR, survival and PFS. The median RT dose was 70 Gy in both arms, with a range of 48-76 Gy in the investigational arm and 18-78 Gy in the control arm. The median duration time of RT was 7.4 weeks (range 4.1-11.7) and 7.3 weeks (range 1.9-10.7), respectively. A total of 27 of the 141 eligible patients received a dose of <70 Gy (19 in the investigational arm versus 18 in the control arm). Ten of these 27 patients received a total dose of <66 Gy (seven versus three), all due to discontinuation of the RT treatment of various reasons. Of the above 10 patients, 3 received a total dose of <60 Gy (one versus two), the one in the investigational arm discontinued RT at 4.5 weeks and the two patients in the control arm at 2 and 5 weeks after the initiation of the treatment. The first of these patients had a CR, the second had an early death at discontinuation and the third had a progression 5 months after RT discontinuation.
QCR in 110 cases revealed that 89 patients (81%) were treated according to the protocol, 16 (14.5%) with a 'minor deviation acceptable' (8 in the investigational arm and 8 in the control arm) and 5 (4.5%) with a 'major deviation acceptable' (2 in the investigational arm and 3 in the control arm). Upon reevaluation therefore, of the RT treatment that was actually delivered rather than intended, five patients were found to have a 'major deviation acceptable' in the following parameters: two patients in the total dose, one in the elapsed treatment days and the field borders, one in the total dose and the elapsed treatment days and one patient in the treatment field borders.
toxicity
Severe toxic effects (grade III and IV) from IC, apart of alopecia (55%), were uncommon. Two patients (3%) developed grade III and four (6%) developed longer grade IV neutropenia. Grade III vomiting was recorded in four patients (6%). One patient suffered a grade IV allergic reaction. Finally, grade III anemia, peripheral neuropathy, fatigue and thrombosis were reported in one patient each. The incidence of severe toxic effects from CCRT is shown in Table 2 . Apart from thrombocytopenia, which was more common in the investigational arm (P = 0.003), and dermatitis, which was more common in the control arm (P = 0.008), the rates of all other toxic effects were similar in both arms. Severe late toxic (11%) stable disease, and 1 patient progressed. At the final 3-month post-CCRT evaluation, 42 patients (58%) in the investigational and 38 (55%) in the control arm achieved CR (P = 0.74). The ORR post-CCRT was 83% and 85% in the investigational and control arm, respectively (P = 0.82) ( Table 3) . Observed agreement between central and local review of the CT scans was 107/117 (91.4%). The kappa statistic (84%, P < 0.001), suggests a strong agreement, when accounting for chance, between central and local radiologists. Multivariate logistic regression revealed that age and clinical stage were independent predictive factors for ORR (Table 4) . Survival status was updated in February 2010. After a median follow-up time of 55 months (range 0.5-76.2), 45 patients (22 versus 23) had tumor progression and 48 patients (25 versus 23) had died. The site of progression was either locoregional only (13 versus 8, P = 0.35) or distant only (7 vs 13, P = 0.15). Four patients experienced both locoregional and distant relapses (two in each arm). So far, 17 (12%) complete responders relapsed (11 versus 6, P = 0.287). Relapse occurred within the first year from diagnosis in eight patients, within the second year in seven and beyond the 2 years in two patients (P = 0.91). The 3-year PFS rates were 64.5% in the investigational and 63.5% in the control arm (P = 0.708). The respective 3-year OS rates were 66.6% and 71.8% (P = 0.652). Univariate Cox regression analysis, adjusted for treatment, for the significant prognostic clinicopathologic parameters, is presented in Table 5 . Kaplan-Meier curves according to treatment group, age, PS and stage are shown in Figure 2 (for OS) and Figure 3 (for PFS) (A, B, C, and D, respectively). Multivariate Cox regression analysis revealed that age, PS, stage and two biomarkers presented in the longer version of this paper (available as supplementary data in Annals of Oncology online), Ki67 and p63, were significant independent predictors for both OS and PFS (Table 6 ).
supportive care
Supportive treatment with hematopoietic growth factors, erythropoietin versus granulocyte colony-stimulating factor, was administered to 20 versus 17 patients, respectively in the The incidence of severe thrombocytopenia was higher in the investigational arm (16% versus 1%, P = 0.003). b The incidence of severe dermatitis was higher in the control arm (6% versus 24%, P = 0.008). 
There were no significant differences in ORR between the two treatment groups (83% versus 85%, P = 0.82). NE for response patients either never started or discontinued treatment or died before evaluation. CCRT, concomitant chemoradiotherapy; CR, complete response; IC, induction chemotherapy; NE, nonevaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.
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investigational arm (five versus eight during IC) and 6 versus 13, respectively in the control arm. Most of these patients received erythropoietin because of grade II anemia. Significantly, more patients (20 versus 6) received erythropoietin in the investigational arm (P = 0.002), however this did not affect the final multivariate model for OS and PFS. Seven patients (three during IC) in the investigational arm and four in the control arm required transfusions with red blood cells, while two patients in the investigational arm required transfusions with platelets during CCRT. Nine patients (four during IC) in the investigational arm and seven in the control arm were hospitalized for various reasons, usually dehydration or severe mucositis. Only a small minority of patients (5% and 7%, respectively) agreed to be fed by a nasogastric tube or by endoscopic gastrostomy. Over 50% of patients in each arm received some type of antifungal or antimicrobial treatment.
discussion
In the present study, we hypothesized that three cycles of IC followed by CCRT would increase locoregional control rate compared with CCRT alone in patients with LA-NPC. To our original articles Annals of Oncology knowledge, this is the first randomized study with such design reported in European patients with NPC. However, a significant difference regarding ORR, the primary end point, was not found.
Possible reasons for this negative result might have been the size of the study, which was not powered to detect a <20% but still biologically meaningful difference in ORR; the observed imbalance in T classification between the two arms; the inclusion of stage IIB patients, which despite being balanced between the two arms may not benefit from the more intensive treatment administered in the investigational armor the fact that IC and CCRT target the same tumor cell population, resulting in a subadditive effect. The most probable explanation for the reduced efficacy of the induction arm, however might have been the significantly smaller percentage of patients receiving optimal cisplatin doses during CCRT in the investigational arm compared with the control arm. Another possibility is that IC might only be of benefit in certain high-risk patients with bulky and/or extensive nodal disease that have higher potential for metastasis and should have only been tested in such patients [10] . Other reasons may well be, although highly unlikely, that three cycles of IC or the CEP regimen itself were not adequate to achieve optimal response, or that IC is only active in patients who would particularly benefit from CCRT. Of course, combination of the above reasons or other unknown factors related to the biological behavior of the host or the tumor itself cannot be excluded.
In addition, no significant differences between arms were seen with regard to the secondary end points, PFS, rate of distant metastases and OS. There was nevertheless a nonsignificant decrease in the number of patients showing distant progression in the investigational arm with 
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a concomitant increase in the number of patients showing locoregional progression. Future larger randomized studies with similar to our design and higher statistical power might show a more pronounced difference. In a recently published study with similar design to ours, Hui et al. [19] randomized 65 eligible patients from Southeastern China with LA-NPC to receive either three cycles of IC with docetaxel and cisplatin followed by CCRT (investigational arm) or to CCRT alone (control arm). Following IC, the ORR in the investigational arm was 82%, almost identical to that reported in this study with the CEP regimen. The ORR post-CCRT was 82.4% in the investigational arm and 61.5% in the control arm, with the difference being nonsignificant. Similarly, in our study, an ORR of 83% and 85% was reported after the completion of CCRT in the two respective treatment groups. Of note, the primary end point in the study by Hui et al. [19] was the incidence of toxicity and not ORR. Therefore, any comparisons between these two similar studies have to be done with caution, since they might be misleading.
In our study, toxicity was generally manageable in both treatment arms. There were no toxic deaths throughout the study. The main severe toxicity during IC, apart from alopecia, was neutropenia, which occurred in six patients only. The rate of neutropenia and neutropenic fever with the CEP regimen is clearly lower than that reported in the Hui et al. [19] study, probably due to the use of docetaxel with cisplatin, as induction regimen in their study.
During CCRT, the most prominent severe side-effects were mucositis, weight loss and leukopenia, as reported in other studies [20] . Thrombocytopenia was significantly more common in the investigational arm, probably due to the previous exposure of patients to the myelosuppressive agents of the IC regimen. On the other hand, severe dermatitis was more prominent in the control arm. There is no obvious explanation for that difference, which might have occurred by chance. The incidence of all other common side-effects was not different between the two arms.
In conclusion, the present study failed to detect a 20% increase in locoregional response rate when using three cycles of IC with the CEP regimen followed by CCRT compared with CCRT alone. The pattern of severe acute toxicity from CCRT, apart from thrombocytopenia and dermatitis, was similar in the two arms. It is hoped that ongoing larger randomized studies with similar to our design and higher statistical power, such as the GORTEC-NPC2006 trial (ClinicalTrials.gov; NCT00828386) or the SINGAPORE-NCC0901 trial (ClinicalTrials.gov; NCT00997906), will further clarify the role of IC in NPC patients treated with CCRT.
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